Results 141 to 150 of about 81,538 (273)

Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. [PDF]

, 2016
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in adults and children worldwide. NAFLD has become a severe health issue and it can progress towards a more severe form of the disease, the non-alcoholic ...
Feldstein, Ariel E, Povero, Davide
core   +2 more sources

Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. [PDF]

, 2017
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality.
Aby, Elizabeth, Agopian, Vatche, Busuttil, Ronald W, French, Samuel W, Grotts, Jonathan F, Jimenez, Melissa A, Saab, Sammy   +6 more
core   +1 more source

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients

Indian Journal of Pathology and Microbiology, 2010
Background: Alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH) are significant forms of liver disease and may progress to end-stage liver disease, cirrhosis and potentially malignant complications.
Singh Deepak, Rastogi Archana, Sakhuja Puja, Gondal Ranjana, Sarin Shiv   +4 more
doaj  

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis [PDF]

, 2019
BACKGROUND: The last decade has seen a rapid growth in the number of clinical trials enrolling patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH).
Adams, Aithal, Andrade, Angulo, Armstrong, Arroyo, Athyros, Avigan, Banderas, Bays, Belfort, Bjornsson, Caldwell, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Cusi, De Denus, De Santis, Dutta, Eijgenraam, Ekstedt, Ekstedt, European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), Fontana, Friedman, Friedman, Giannini, Guha, Hayashi, Hoofnagle, Hyysalo, Im, Jalan, Kaplan, Kleiner, Kleiner, Kolwankar, Kowdley, Kullak-Ublick, Kwok, LaBrecque, Lavine, Lewis, Lewis, Liddle, Lo Re, Loomba, Maurice, McPherson, Moylan, Mudaliar, Neuschwander-Tetri, Panteghini, Pantsari, Patel, Patel, Pfeffer, Ratziu, Ratziu, Regev, Reid, Robles-Diaz, Rockstroh, Russo, Sanyal, Sanyal, Sanyal, Scorletti, Senior, Siddiqui, Stefan, Tarantino, Temple, Valenti, Verna, Vilar-Gomez, Vuppalanchi, Vuppalanchi, Vuppalanchi, Watkins, Weltman, Wong, Younossi, Younossi, Zelber-Sagi, Zhou, Zimmerman   +91 more
core   +1 more source

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. [PDF]

, 2011
AIMS: Non-alcoholic fatty liver disease (NAFLD) is a complex disease trait where genetic variations and environment interact to determine disease progression.
Al Serri, Ahmad, Anstee, Quentin M, Daly, Ann K, Day, Christopher P, Dongiovanni, Paola, Fargion, Silvia, Fracanzani, Anna, Leathart, Julian B S, Nobili, Valerio, Patch, Julia, Valenti, Luca   +10 more
core   +1 more source

Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease

Open Medicine, 2018
There are few effective medications for non-alcoholic steatohepatitis (NASH). We investigated the efficacy of ipragliflozin (selective sodium-glucose cotransporter-2 inhibitor [SGLT2I]) for the treatment of patients with type 2 diabetes mellitus (T2DM ...
Miyake Teruki, Yoshida Sakiko, Furukawa Shinya, Sakai Takenori, Tada Fujimasa, Senba Hidenori, Yamamoto Shin, Koizumi Yohei, Yoshida Osamu, Hirooka Masashi, Kumagi Teru, Niiya Tetsuju, Miyaoka Hiroaki, Masanori Abe, Matsuura Bunzo, Hiasa Yoichi   +15 more
doaj   +1 more source

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2010
The aim of review. To cite the literature data, confirming efficacy of ursodeoxycholic acid (UDCA) at alcoholic and non-alcoholic steatohepatitis (NASH).Original positions.
Ye. A. Fedos’ina, M. V. Mayevskaya
doaj  

Comprehensive treatment of patients with type 2 diabetes, complicated by diabetic kidney disease, with concomitant non-alcoholic steatohepatitis

Mìžnarodnij Endokrinologìčnij Žurnal
Background. The purpose of research is to establish the effect of bicyclol on the clinical manifestations of non-alcoholic steatohepatitis (NASH), markers of liver damage in patients with non-alcoholic steatohepatitis, and diabetes mellitus type 2 (DM2),
Z.Ya. Kotsiubiichuk, А.А. Antoniv, O.V. Kaushanska, L.V. Kanovska, Yu.M. Yarinich   +4 more
doaj   +1 more source

Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond

Biomedicines
Non-alcoholic fatty liver disease (NAFLD) is a widespread contributor to chronic liver disease globally. A recent consensus on renaming liver disease was established, and metabolic dysfunction-associated steatotic liver disease, MASLD, was chosen as the ...
Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo   +3 more
doaj   +1 more source

Pharmacological effects of gastrodin: Insight into neurological diseases and mechanism in ferroptosis and pyroptosis

Ibrain, Volume 11, Issue 1, Page 74-83, Spring 2025.
Pharmacological effects of gastrodin include prevention and treatment of cognitive decline and reperfusion injuries, anticonvulsion, antiepilepsy, antidepressants, and analgesia, which are related to antiferroptosis and antipyroptosis. Abstract Gastrodin, as an effective monomer of gastrodia elata, plays a significant role in anti‐inflammatory ...
Xue Zheng, Jing Li, Zhao‐Qiong Zhu
wiley   +1 more source